UniProt ID | HRG_MOUSE | |
---|---|---|
UniProt AC | Q9ESB3 | |
Protein Name | Histidine-rich glycoprotein | |
Gene Name | Hrg | |
Organism | Mus musculus (Mouse). | |
Sequence Length | 525 | |
Subcellular Localization | Secreted. | |
Protein Description | Plasma glycoprotein that binds a number of ligands such as heme, heparin, heparan sulfate, thrombospondin, plasminogen, and divalent metal ions. Binds heparin and heparin/glycosaminoglycans in a zinc-dependent manner. Binds heparan sulfate on the surface of liver, lung, kidney and heart endothelial cells. Binds to N-sulfated polysaccharide chains on the surface of liver endothelial cells. Inhibits rosette formation. Acts as an adapter protein and is implicated in regulating many processes such as immune complex and pathogen clearance, cell chemotaxis, cell adhesion, angiogenesis, coagulation and fibrinolysis. Mediates clearance of necrotic cells through enhancing the phagocytosis of necrotic cells in a heparan sulfate-dependent pathway. This process can be regulated by the presence of certain HRG ligands such as heparin and zinc ions. Binds to IgG subclasses of immunoglobins containing kappa and lambda light chains with different affinities regulating their clearance and inhibiting the formation of insoluble immune complexes. Tethers plasminogen to the cell surface. Binds T-cells and alters the cell morphology. Acts as a regulator of the vascular endothelial growth factor (VEGF) signaling pathway; inhibits endothelial cell motility by reducing VEGF-induced complex formation between PXN/paxillin and ILK/integrin-linked protein kinase and by promoting inhibition of VEGF-induced tyrosine phosphorylation of focal adhesion kinases and alpha-actinins in endothelial cells. Also plays a role in the regulation of tumor angiogenesis and tumor immune surveillance. Normalizes tumor vessels and promotes antitumor immunity by polarizing tumor-associated macrophages, leading to decreased tumor growth and metastasis (By similarity). Modulates angiogenesis by blocking the CD6-mediated antiangiongenic effect of thrombospondins, THBS1 and THBS2.. | |
Protein Sequence | MKVLTTALLLVTLQCSHALSPTNCDASEPLAEKVLDLINKGRRSGYVFELLRVSDAHLDRAGTATVYYLALDVIESDCWVLSTKAQDDCLPSRWQSEIVIGQCKVIATRYSNESQDLSVNGYNCTTSSVSSALRNTKDSPVLLDFFEDSELYRKQARKALDKYKTDNGDFASFRVERAERVIRARGGERTNYYVEFSMRNCSTQHFPRSPLVFGFCRALLSYSIETSDLETPDSIDINCEVFNIEDHKDTSDMKPHWGHERPLCDKHLCKLSGSRDHHHTHKTDKLGCPPPPEGKDNSDRPRLQEGALPQLPPGYPPHSGANRTHRPSYNHSCNEHPCHGHRPHGHHPHSHHPPGHHSHGHHPHGHHPHSHHSHGHHPPGHHPHGHHPHGHHPHGHHPHGHHPHGHDFLDYGPCDPPSNSQELKGQYHRGYGPPHGHSRKRGPGKGLFPFHHQQIGYVYRLPPLNIGEVLTLPEANFPSFSLPNCNRSLQPEIQPFPQTASRSCPGKFESEFPQISKFFGYTPPK | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
24 | S-palmitoylation | HALSPTNCDASEPLA CCCCCCCCCCCHHHH | 5.21 | 26165157 | |
89 | S-palmitoylation | STKAQDDCLPSRWQS ECCCCCCCCCCHHCC | 8.95 | 26165157 | |
112 | N-linked_Glycosylation | VIATRYSNESQDLSV EEEEECCCCCCCEEE | 43.96 | - | |
123 | N-linked_Glycosylation | DLSVNGYNCTTSSVS CEEECCEECCHHHHH | 20.32 | - | |
200 | N-linked_Glycosylation | YVEFSMRNCSTQHFP EEEEECCCCCCCCCC | 18.56 | 17330941 | |
288 | S-palmitoylation | HKTDKLGCPPPPEGK CCCCCCCCCCCCCCC | 7.10 | 26165157 | |
322 | N-linked_Glycosylation | YPPHSGANRTHRPSY CCCCCCCCCCCCCCC | 53.56 | - | |
330 | N-linked_Glycosylation | RTHRPSYNHSCNEHP CCCCCCCCCCCCCCC | 25.57 | - | |
438 | Phosphorylation | YGPPHGHSRKRGPGK CCCCCCCCCCCCCCC | 44.05 | - | |
449 | Phosphorylation | GPGKGLFPFHHQQIG CCCCCCCCCCCCCCE | 32.48 | 24719451 | |
485 | S-palmitoylation | PSFSLPNCNRSLQPE CCCCCCCCCCCCCCC | 4.17 | 26165157 | |
504 | S-palmitoylation | PQTASRSCPGKFESE CCCCCCCCCCCCHHC | 5.11 | 26165157 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of HRG_MOUSE !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of HRG_MOUSE !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of HRG_MOUSE !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
Oops, there are no PPI records of HRG_MOUSE !! |
Kegg Drug | ||||||
---|---|---|---|---|---|---|
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
N-linked Glycosylation | |
Reference | PubMed |
"Enhanced analysis of the mouse plasma proteome using cysteine-containing tryptic glycopeptides."; Bernhard O.K., Kapp E.A., Simpson R.J.; J. Proteome Res. 6:987-995(2007). Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-200, AND MASSSPECTROMETRY. |